Recent PD1/PD-L1 checkpoint inhibitors have demonstrated durable response and clinical benefits in MCC patients; however, a significant portion of MCC patients either do not respond or acquire resistance, eventually succumbing to their diseases. Here, CD274 is linked to Merkel cell skin cancer.